![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Evgen Pharma Plc | LSE:EVG | London | Ordinary Share | GB00BSVYN304 | ORD 0.25P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.80 | 0.75 | 0.85 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 422k | -4.04M | -0.0147 | -0.54 | 2.2M |
Date | Subject | Author | Discuss |
---|---|---|---|
31/8/2023 12:07 | It seems to me that there is still a bigger seller in the background, as MM sold that last 100k after your buy at 2.24p hat. The lower we go the more likely there are bigger sellers that purchased under 3.5p I guess. It will be interesting to see at what point there is bounce and a lot of support in the current flat market, and if it bounces at any pace if at all. | ![]() clocktower | |
31/8/2023 11:41 | Revalidating my research and taking advantage of the current weakness to top up. So thank you for selling out and any others that have done so. I don't punt Clock | ![]() hatfullofsky | |
31/8/2023 11:25 | Buying back some of what you sold of this in the past by any chance hut, as a punt? :-) Good Luck either way, I might do the same lower down the food chain. | ![]() clocktower | |
31/8/2023 10:51 | BTW I asked GPT to analyse the Phase 1b release, very interesting. Here's an extract : Changes in Gene Expression: The fact that changes in gene expression were observed indicates that the drug, SFX-01, has effects at a genetic level. This is generally a positive outcome, as it suggests that the drug is interacting with the body's molecular processes in a way that leads to measurable changes. Effects in Healthy Volunteers: The press release specifically mentions that these gene expression changes were observed "even in healthy volunteers." This is noteworthy because it suggests that the drug's effects on gene expression are not limited to individuals with specific conditions but are observable in a general population. This broader impact could have implications for the drug's potential therapeutic applications. | ![]() hatfullofsky | |
31/8/2023 10:49 | Sell volume value is only GBP15k so not a major shareholder. Zero liquidity anywhere in the market and especially at EVG any sells tank the share price They have cash into Q4 2024 and study results on 3 fronts due this year. The 100k was a buy, by me | ![]() hatfullofsky | |
31/8/2023 10:45 | Have you finished selling clock ? | ![]() hatfullofsky | |
31/8/2023 10:16 | You better hope it is not Kight tossing in the towel. | ![]() clocktower | |
31/8/2023 09:18 | Someone else seems to be throwing in the towel today. It is going to be a hard task to get back to the target of 7/8p now markth in the next year or two imo. Good Luck. | ![]() clocktower | |
30/8/2023 22:38 | Just thought I would double check hat and took the following from the report: “ Share options may be granted under the LTIP as follows: ï An initial award to Executive Directors on joining the Company to support the recruitment and drive retention. ï An annual award to Executive Directors and other staff members to be made around the time of the AGM, though this may be deferred in the event of staff having inside information. Since 2021 vesting of share options has been subject to; a shareholder return metric (30%), delivery of strategic corporate objectives (40%), and time-vesting 3 years from grant (30%). The aims of this structure are to continue to align senior management remuneration with shareholder returns and to support staff retention. Achievement of the shareholder return metric depends on absolute share price performance. For the 2022/23 year grants, if the share price is between 8p and 38p (based on the non-volume weighted mean average price over the 3 months preceding the vesting date), options will vest on a straight-line basis between nil and 100% of the 30% shareholder return metric. The 2021/22 year grants are similarly assessed, save that the share price range is between 12p and 38p. Details of the awards can be seen on page 27. | ![]() clocktower | |
30/8/2023 22:38 | Hatfull - where did you get 38p strike price from. The shares were initially issued at 35p 10 years ago so that's just make believe. And now you know why I post on here to counter some of the more outlandish statements. Aim is truly the wild west of investing. | ![]() kingalf | |
30/8/2023 21:26 | The dilutive comment was taken from the 2023 annual report.I guess 10% of the share capital in options could be considered dilutive. Strikes are up to 38p | ![]() hatfullofsky | |
30/8/2023 21:10 | hat, although the last options were nil paid as far as I can recall, I am not so sure when you state they could potential be dilutive, as I thought there was a strike price that was above the current share price and some as high as 10p unless my memory is confused but it was all set out in the last full year accounts which are available online if anyone wants to check. Please correct me if I am wrong as I would not like to mislead or try to run the share price lower just to jump back in if I felt the news justified it. Usually there is a bit of insider buying just before major price changing news but that is yet to show its head. | ![]() clocktower | |
30/8/2023 19:15 | Why would the directors need to buy when they have so many options ? 10 Employees (6 directors) At 31/03/23 there were 20.7m (10% of the share capital) options outstanding (2022 10.6m), which are potentially dilutive (13m Directors Share Options) Huw Jones 9m Barry Clare 1.2m Richard Moulson 2.35m Others 0.2m | ![]() hatfullofsky | |
30/8/2023 18:27 | Due in the next 4 months $500k Phase IIb milestone payment Breast Cancer study findings Colorectal Cancer study findings Radio Sensitisation study findings | ![]() hatfullofsky | |
30/8/2023 17:36 | Just wish kight would show more of his hand | ![]() markth126 | |
30/8/2023 17:18 | Balls of Steel | ![]() hatfullofsky | |
30/8/2023 17:05 | I'm now way over 3.5m and my comfort zone but holding for a payout soon in personal opinion. Will never sell them all until buyout deal but posed to top slice at 7/8p. Good luck all. No stop loss for me and got to be in it to win it. | ![]() markth126 | |
30/8/2023 16:55 | They are in discussions with partner for breast cancer so can't as it's sensitive information. Probably a deal before the end of the year. | ![]() wololol | |
30/8/2023 16:35 | just tell me here - I don't have time to watch past presentations. | ![]() farrugia | |
30/8/2023 14:14 | Watch the investor meet presentations and you will find out. Old news bro | ![]() wololol | |
30/8/2023 13:35 | my question is why is there almost no director buys? | ![]() farrugia | |
29/8/2023 18:10 | Well let's hope these significant contracts come to fruition. So much expense and so little to show for it. Stil, we have the die hard supporters who should really be a little annoyed with the bods but blindly keep the faith. I'm starting to think that some of the most ardent supporters on here are infact the bods themselves. | ![]() kingalf |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions